Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) trades at $0.64 with AI Score 55/100 (Grade B). Beijing Tong Ren Tang Chinese Medicine Company Limited manufactures, retails, and wholesales Chinese medicine and healthcare products. Market cap: $535.91M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BJTRF: BJTRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BJTRF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BJTRF: 5/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) Healthcare & Pipeline Overview
Beijing Tong Ren Tang Chinese Medicine Company Limited, founded in 1669, is a global manufacturer, retailer, and wholesaler of Chinese medicine and healthcare products, operating across Hong Kong, Mainland China, and overseas markets, with a focus on traditional Chinese medicine and consultation services.
What Is the Investment Thesis for BJTRF?
Beijing Tong Ren Tang Chinese Medicine Company Limited presents a compelling investment case based on its established brand, global presence, and consistent profitability. With a P/E ratio of 14.5 and a profit margin of 30.2%, the company demonstrates financial stability. A dividend yield of 4.09% provides an attractive return for investors. Growth catalysts include expansion in overseas markets and increased demand for traditional Chinese medicine. However, investors may want to evaluate risks such as regulatory changes and competition from other pharmaceutical companies. The company's beta of 0.36 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
BJTRF Key Highlights
- Market capitalization of $535.91M, reflecting the company's substantial size and market presence.
- P/E ratio of 14.5, indicating a potentially undervalued stock compared to its earnings.
- Profit margin of 30.2%, showcasing strong profitability and efficient operations.
- Gross margin of 63.0%, demonstrating the company's ability to maintain high profitability on its products.
- Dividend yield of 4.09%, providing a steady income stream for investors.
Who Are BJTRF's Competitors?
BJTRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AGYTF Allergy Therapeutics plc | $0.15 | +7.14% | $756.30M | 59 |
| AVNBF Avon Technologies Plc | $21.28 | -5.37% | $626.73M | 38 |
| BOIRF Boiron S.A. | $31.50 | +5.00% | $546.91M | 43 |
| CLVSF CellaVision AB (publ) | $14.00 | +0.00% | $333.92M | 52 |
| FDMDF 4DMedical Limited | $2.80 | -6.67% | $1.67B | 61 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BJTRF's Key Strengths?
- Strong brand recognition and heritage.
- Global presence and distribution network.
- Integrated business model.
- High profit margin (30.2%).
What Are BJTRF's Weaknesses?
- Reliance on traditional Chinese medicine, which may not appeal to all consumers.
- Exposure to regulatory risks in different countries.
- Potential for counterfeit products to damage brand reputation.
- Limited product diversification beyond traditional Chinese medicine.
What Could Drive BJTRF Stock Higher?
- Expansion of retail outlets in new international markets by Q4 2026, targeting regions with growing interest in traditional Chinese medicine.
- Increasing demand for traditional Chinese medicine due to growing consumer interest in natural and alternative therapies.
- Product innovation and development, with a focus on creating new formulations and dosage forms for existing products.
- Strategic partnerships and collaborations with hospitals, clinics, and pharmacies to expand distribution channels.
- Launch of new e-commerce platform in Q2 2026 to enhance online sales and customer engagement.
What Are the Key Risks for BJTRF?
- Changes in government regulations regarding traditional Chinese medicine could impact the company's operations.
- Competition from other pharmaceutical companies and manufacturers of traditional Chinese medicine products.
- Economic downturns could affect consumer spending on healthcare products and services.
- Negative publicity related to product safety or efficacy could damage the company's brand reputation.
- Trading on the OTC market carries inherent risks due to limited regulation and disclosure.
What Are the Growth Opportunities for BJTRF?
- Expansion in Overseas Markets: Beijing Tong Ren Tang has the opportunity to further expand its presence in overseas markets, particularly in regions with a growing interest in traditional Chinese medicine. The global herbal medicine market is projected to reach $129.3 billion by 2028, presenting a significant growth opportunity. By increasing its retail outlets and distribution networks in Asia, Oceania, North America, and Europe, the company can tap into this growing demand and increase its revenue streams. This expansion can be achieved through strategic partnerships, acquisitions, and organic growth initiatives.
- Increased Demand for Traditional Chinese Medicine: As consumers increasingly seek natural and alternative healthcare solutions, the demand for traditional Chinese medicine is expected to rise. Beijing Tong Ren Tang can capitalize on this trend by promoting the benefits of its products and services through targeted marketing campaigns and educational initiatives. The global traditional medicine market is estimated to reach $210 billion by 2026, indicating a substantial growth potential. By leveraging its established brand and reputation, the company can attract new customers and increase its market share.
- Product Innovation and Development: Beijing Tong Ren Tang can drive growth by investing in research and development to create new and innovative products that meet the evolving needs of consumers. This includes developing new formulations, dosage forms, and delivery methods for its traditional Chinese medicines. The company can also explore opportunities to integrate traditional Chinese medicine with modern healthcare practices. By staying at the forefront of product innovation, Beijing Tong Ren Tang can maintain its competitive edge and attract a wider customer base.
- Strategic Partnerships and Collaborations: Beijing Tong Ren Tang can accelerate its growth by forming strategic partnerships and collaborations with other companies in the healthcare industry. This includes partnering with hospitals, clinics, and pharmacies to offer its products and services to a wider audience. The company can also collaborate with research institutions to conduct clinical trials and validate the efficacy of its traditional Chinese medicines. By leveraging the expertise and resources of its partners, Beijing Tong Ren Tang can expand its reach and enhance its credibility.
- E-commerce and Digital Marketing: Beijing Tong Ren Tang can enhance its online presence and reach a wider audience by investing in e-commerce and digital marketing initiatives. This includes developing a user-friendly online store, optimizing its website for search engines, and engaging with customers through social media channels. The global e-commerce market is projected to reach $6.54 trillion in 2023, presenting a significant opportunity for the company to increase its online sales. By leveraging digital technologies, Beijing Tong Ren Tang can improve its customer engagement and drive revenue growth.
What Opportunities Does BJTRF Have?
- Expansion into new geographic markets.
- Development of new and innovative products.
- Increased demand for natural and alternative healthcare solutions.
- Strategic partnerships and collaborations.
What Threats Does BJTRF Face?
- Competition from other pharmaceutical companies.
- Changes in government regulations.
- Economic downturns affecting consumer spending.
- Negative publicity related to product safety or efficacy.
What Are BJTRF's Competitive Advantages?
- Established brand recognition and reputation (Tong Ren Tang).
- Long history and heritage in traditional Chinese medicine (founded in 1669).
- Global presence with retail outlets in multiple countries.
- Integrated business model encompassing manufacturing, retail, and wholesale.
What Does BJTRF Do?
Founded in 1669, Beijing Tong Ren Tang Chinese Medicine Company Limited has a rich history rooted in traditional Chinese medicine. Originally serving the imperial court, the company has evolved into a modern enterprise while maintaining its commitment to traditional practices. Today, Beijing Tong Ren Tang engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products. Its operations are divided into three segments: Hong Kong, Mainland China, and Overseas. The company offers a wide range of products, including traditional Chinese medicines, health supplements, and personal care items, marketed under the well-known Tong Ren Tang brand. In addition to its product offerings, the company provides Chinese medical consultation and treatment services through its retail outlets. Beijing Tong Ren Tang operates 23 retail outlets in Hong Kong and 46 retail outlets in other countries and regions across Asia, Oceania, North America, and Europe, demonstrating its global reach and commitment to providing traditional Chinese medicine solutions worldwide. The company's headquarters are located in Wan Chai, Hong Kong.
What Products and Services Does BJTRF Offer?
- Manufactures traditional Chinese medicine products.
- Retails Chinese medicine and healthcare products.
- Wholesales Chinese medicine and healthcare products to distributors.
- Offers Chinese medical consultation services.
- Provides Chinese medical treatment services.
- Operates retail outlets in Hong Kong, Mainland China, and overseas.
- Markets products under the Tong Ren Tang brand.
How Does BJTRF Make Money?
- Manufactures and sells Chinese medicine and healthcare products.
- Operates retail outlets for direct sales to consumers.
- Distributes products through wholesale channels.
- Generates revenue from medical consultations and treatments.
What Industry Does BJTRF Operate In?
Beijing Tong Ren Tang operates within the global healthcare industry, specifically in the traditional Chinese medicine (TCM) sector. The TCM market is experiencing growth due to increasing consumer interest in natural and alternative therapies. The company faces competition from other TCM manufacturers and pharmaceutical companies. The industry is subject to regulatory oversight, ensuring product safety and efficacy. Beijing Tong Ren Tang's established brand and global presence provide a competitive advantage in this evolving market.
Who Are BJTRF's Key Customers?
- Individuals seeking traditional Chinese medicine products.
- Wholesalers and distributors of healthcare products.
- Patients seeking Chinese medical consultations and treatments.
- Retail customers in Hong Kong, Mainland China, and overseas.
FY2026 estForward Outlook
Wall Street analysts project Beijing Tong Ren Tang Chinese Medicine Company Limited revenue of about $1.66B for fiscal 2026, with EPS near $0.59.
F-Score 7/9Financial Health
Beijing Tong Ren Tang Chinese Medicine Company Limited's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 11.59 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 10%Key Financial Metrics
Return on equity for Beijing Tong Ren Tang Chinese Medicine Company Limited stands at 9.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.5%, showing how much profit it generates from its asset base. BJTRF trades at a trailing price-to-earnings ratio of 14.46, below the Healthcare sector average of ~23x. Its free cash flow yield is 14.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.9%, the inverse of the P/E and a quick read on earnings relative to price.
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) Valuation Context
Valued at $535.91M, BJTRF is classified as a small-cap stock. Relative to its peer group, BJTRF's quantitative score of 55/100 is roughly in line with the peer average of 51/100.
BJTRF Revenue & Earnings Trend
In Q4 2025, BJTRF generated $751.4M in top-line revenue, marking a sequential increase of 97.3%. The company recorded net income of $162.3M, with diluted EPS of $0.19. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, BJTRF averaged $0.16 in diluted EPS.
Company Profile
Beijing Tong Ren Tang Chinese Medicine Company Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Wan Chai, HK. The company is led by CEO Wang Chi. BJTRF has traded publicly since 2021.
BJTRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future performance, indicating that leadership believes in its growth.
- Community sentiment has shifted positively, with discussions highlighting the increasing demand for traditional Chinese medicine amid a global wellness trend.
- The company has been expanding its international presence, tapping into new markets which could drive revenue growth and brand recognition.
- Recent product launches have received favorable reviews, enhancing the company's image and attracting new customers.
Bear Case
- Concerns over regulatory scrutiny in the herbal medicine sector may impact operational flexibility and growth prospects.
- Community discussions reflect skepticism regarding the sustainability of recent sales spikes, with some fearing they may be temporary.
- Increased competition from both local and international players could pressure market share and profitability in the coming months.
- Supply chain issues reported recently could hinder production capabilities, affecting the company's ability to meet growing demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $751M | $162M | $0.19 |
| Q2 2025 | $381M | $117M | $0.14 |
| Q1 2025 | $380M | $117M | $0.14 |
| Q4 2024 | $474M | $140M | $0.17 |
Based on FMP financials and quantitative analysis
BJTRF Latest News
No recent news available for BJTRF.
BJTRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BJTRF.
Price Targets
Wall Street price target analysis for BJTRF.
BJTRF MoonshotScore
What does this score mean?
The MoonshotScore rates BJTRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wang Chi
Unknown
Information on Wang Chi's background is not available in the provided data. Without additional context, it is difficult to provide a detailed biography. Further research would be needed to ascertain his career history, educational background, and previous roles.
Track Record: Information on Wang Chi's track record is not available in the provided data. It is unknown what key achievements, strategic decisions, or company milestones have occurred under his leadership. Further research would be needed to assess his performance as CEO.
BJTRF OTC Market Information
The OTC Other tier, where Beijing Tong Ren Tang Chinese Medicine Company Limited trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet specific listing requirements, resulting in higher risks for investors due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Wider bid-ask spreads increase transaction costs.
- Potential for fraud or manipulation is higher on the OTC market.
- Lack of regulatory oversight increases investment risk.
- Verify the company's registration and regulatory filings.
- Review available financial statements and assess financial health.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or reports of regulatory issues.
- The company has been in business since 1669.
- The company has a global presence with retail outlets in multiple countries.
- The company markets its products under the Tong Ren Tang brand.
- The company has a history of profitability.
- The company has a dividend yield of 4.09%.
Common Questions About BJTRF (Healthcare)
What does Beijing Tong Ren Tang Chinese Medicine Company Limited do?
Beijing Tong Ren Tang Chinese Medicine Company Limited is involved in the manufacturing, retailing, and wholesaling of traditional Chinese medicine and healthcare products. Operating through segments in Hong Kong, Mainland China, and overseas, the company also provides Chinese medical consultation and treatment services. With a history dating back to 1669, the company leverages its established brand to serve both individual consumers and wholesale distributors across Asia, Oceania, North America, and Europe, offering a range of products under the Tong Ren Tang brand.
What are the main risks for BJTRF?
The main risks for Beijing Tong Ren Tang Chinese Medicine Company Limited include regulatory changes impacting the traditional Chinese medicine industry, competition from other pharmaceutical companies, and economic downturns affecting consumer spending. Trading on the OTC market also presents risks due to limited regulation and disclosure. Additionally, negative publicity related to product safety or efficacy could damage the company's brand reputation. Investors should carefully consider these factors before investing in BJTRF.
What are the key factors to evaluate for BJTRF?
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) holds an AI score of 55/100 (moderate). P/E: 14.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does BJTRF data refresh on this page?
BJTRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BJTRF's recent stock price performance?
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and heritage. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BJTRF overvalued or undervalued right now?
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) trades at 14.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BJTRF?
Before investing in Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BJTRF to a portfolio?
Key strength of Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF): Strong brand recognition and heritage. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.